UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C

By: via Benzinga
Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III clinical trials in patients ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.